Physician profile
Austin E Garza
NPI 1710967260
$5,679.49
in general payments reported to CMS, 2019-2025
32 companies · $919 in 2025
The $919 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,067 · 2020: $862 · 2021: $165 · 2022: $454 · 2023: $607 · 2024: $606 · 2025: $919.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,113 · Education: $18.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,113.23 |
| Education | $18.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,273.89 | 2019-2024 | Axios |
| Abbvie INC. | $1,051.04 | 2019-2025 | |
| Janssen Biotech, INC. | $301.97 | 2019-2025 | Tremfya, Stelara, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $249.58 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $195.74 | 2019-2025 | Xifaxan |
| Celgene Corporation | $184.61 | 2021-2024 | Zeposia |
| Pfizer INC. | $175.83 | 2019-2025 | |
| Genzyme Corporation | $141.58 | 2022-2025 | |
| Ardelyx, INC. | $132.25 | 2023-2025 | Ibsrela |
| Ethicon US, LLC | $117.22 | 2019 | |
| Intercept Pharmaceuticals, INC. | $96.81 | 2019-2024 | Ocaliva |
| Gilead Sciences, INC. | $86.45 | 2021-2023 | |
| Olympus America INC. | $69.57 | 2025 | Single Use Aspiration Needle Na-U200h |
| Shionogi INC | $67.54 | 2019-2020 | |
| Lilly USA, LLC | $58.47 | 2023-2025 | Omvoh |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $51.08 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $49.40 | 2024-2025 | Resmetirom, Rezdiffra |
| Regeneron Healthcare Solutions, INC. | $45.90 | 2023-2025 | Dupixent |
| Ferring Pharmaceuticals INC. | $45.61 | 2019-2023 | Rebyota |
| Nestle Healthcare Nutrition INC. | $41.57 | 2021-2023 | |
| Celltrion USA INC. | $35.89 | 2024 | Zymfentra, Vegzelma |
| Aimmune Therapeutics, INC. | $34.23 | 2024-2025 | Vowst |
| E.R. Squibb & Sons, L.L.C. | $23.63 | 2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $22.16 | 2022 | |
| Merck Sharp & Dohme LLC | $21.35 | 2024 | Dificid |
| Enterra Medical, INC. | $20.61 | 2022 | |
| Daiichi Sankyo INC. | $16.29 | 2019 | |
| Alexion Pharmaceuticals, INC. | $16.03 | 2019 | |
| Endo Pharmaceuticals INC. | $14.80 | 2019 | |
| Qol Medical, LLC | $14.37 | 2019 | |
| Allergan, INC. | $12.35 | 2019 | |
| Braintree Laboratories, INC. | $11.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Austin Garza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.